Research by Chicre et al. found that Janus kinase inhibitors may significantly increase the risk of major adverse cardiac events and all-cause death in patients with rheumatoid arthritis (RA) when compared with other RA treatments. This study highlights the need for more comparative safety studies.
Supplemental Vitamin D May Not Protect Against Fractures in Healthy Adults
Supplemental vitamin D may not significantly lower the risk of fractures in generally healthy adults compared with placebo, according to a large study by LeBoff et al.
Point-of-Care Uric Acid Testing
In June 2022, I listened to several presentations on gout at EULAR’s European Congress of Rheumatology. Most began with data confirming a sad truth that we, as rheumatology providers, are all aware of: too many patients are taking subtherapeutic doses of urate-lowering therapy (ULT).1,2 Recommendations from the American College of Physicians in 2017 advocated for…
2022 ACR Guideline for Vaccinations in Patients with RMDs
This guideline provides evidence-based recommendations on the use of vaccinations in children and adults with rheumatic and musculoskeletal diseases. It includes expanded indications for some vaccines, as well as guidance on whether to hold immunosuppressive medications or delay vaccination to maximize vaccine immunogenicity and efficacy.
Useful Data Made Easy: The ACR RISE Registry
A qualified clinical data registry, RISE helps clinicians measure their performance on quality measures, identify ways to improve their patient care experience, navigate Medicare reporting and demonstrate the value of rheumatology to key influencers. Practices must join no later than June 30 to use RISE for 2023 Traditional MIPS or Advancing Rheumatology Patient Care MVP reporting.
What to Expect in Healthcare Policy from the 2023 State Legislative Sessions
With 2023 state legislative sessions underway, early prevailing themes may forecast areas where we will see gains this year. Key issues include utilization management, copay accumulator bans, white bagging and pharmacy benefit manager reform.
FDA Approves Abaloparatide to Treat Men with Osteoporosis & a High Risk of Fracture
In late December, the FDA approved subcutaneous abaloparatide for the treatment of men with osteoporosis at a high risk of fracture. This approval is based on a placebo-controlled study that showed abaloparatide led to significant increases in bone mineral density of the lumbar spine, total hip and femoral neck. Abaloparatide was approved in April 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Healthcare Policy Prospects in the 118th Congress
The U.S. government remains divided. Democrats hold the White House and the Senate by one vote, and Republicans lead the House. Amid this division, the ACR is watching possible areas to advance healthcare legislation. Meet the committees and members with the largest jurisdiction over healthcare policy.
Reform of Medicare Payment System Needed to Maintain Patient Care, ACR Says
In a joint letter, the ACR urges Congress to undergo comprehensive reform of the Medicare payment system and seek long-term payment solutions that will allow clinicians to continue to care for Medicare patients.
How Long Should Methotrexate Be Held Following Seasonal Vaccinations?
Vaccinations against preventable diseases, including seasonal influenza, are strongly recommended for patients with rheumatoid arthritis (RA), who are at increased risk of infections as a result of underlying immune dysfunction and treatment-induced immunosuppression. Park et al. conducted this clinical trial to investigate whether discontinuing methotrexate for one week after seasonal influenza vaccination is noninferior to discontinuing it for two weeks after vaccination in patients with RA.
- « Previous Page
- 1
- …
- 27
- 28
- 29
- 30
- 31
- …
- 308
- Next Page »